Prescription for American Drug Independence Act of 2020

Prescription for American Drug Independence Act of 2020

This bill requires the Department of Health and Human Services to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine to (1) establish a committee of experts on drug-supply issues, (2) convene a symposium to recommend strategies for ending U.S. dependence on foreign manufacturing of critical drugs, and (3) report on the symposium's proceedings.

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6670 Introduced in House (IH)]

<DOC>






116th CONGRESS
  2d Session
                                H. R. 6670

   To provide for an exploration of strategies to increase domestic 
manufacturing and diversify the supply chain of critical drugs, and for 
                            other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 1, 2020

   Ms. Eshoo (for herself and Mrs. Brooks of Indiana) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
   To provide for an exploration of strategies to increase domestic 
manufacturing and diversify the supply chain of critical drugs, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Prescription for American Drug 
Independence Act of 2020''.

SEC. 2. NATIONAL ACADEMIES STRATEGIES TO INCREASE DOMESTIC 
              MANUFACTURING OF CRITICAL DRUGS.

    (a) In General.--Not later than 14 days after the date of enactment 
of this Act, the Secretary of Health and Human Services shall enter 
into an agreement with the National Academies of Sciences, Engineering, 
and Medicine (referred to in this section as the ``National 
Academies'') under which, not later than 90 days after the date of 
entering into the agreement, the National Academies will--
            (1) establish a committee of experts who are knowledgeable 
        about drug supply issues, including--
                    (A) sourcing and production of critical drugs;
                    (B) sourcing and production of active 
                pharmaceutical ingredients in critical drugs;
                    (C) the raw materials and other components for 
                critical drugs; and
                    (D) the public health and national security 
                implications of the current supply chain for critical 
                drugs;
            (2) convene a public symposium to--
                    (A) analyze the impact of United States dependence 
                on the foreign manufacturing of critical drugs on 
                patient access and care, including in hospitals and 
                intensive care units; and
                    (B) recommend strategies to end United States 
                dependence on foreign manufacturing to ensure the 
                United States has a diverse and vital supply chain for 
                critical drugs to protect the Nation from natural or 
                hostile occurrences; and
            (3) submit a report on the symposium's proceedings to the 
        Congress and publish a summary of such proceedings on the 
        public website of the National Academies.
    (b) Symposium.--In carrying out the agreement under subsection (a), 
the National Academies shall consult with--
            (1) the Department of Health and Human Services, the 
        Department of Homeland Security, the Department of Defense, the 
        Department of Commerce, the Department of State, the Department 
        of Veterans Affairs, the Department of Justice, and any other 
        Federal agencies as appropriate; and
            (2) relevant stakeholders, including drug manufacturers, 
        health care providers, medical professional societies, State-
        based societies, public health experts, State and local public 
        health departments, State medical boards, patient groups, 
        health care distributors, wholesalers and group purchasing 
        organizations, pharmacists, and other entities with experience 
        in health care and public health, as appropriate.
    (c) Definitions.--For the purposes of this section:
            (1) The term ``critical drug'' means a drug that is 
        described in subsection (a) of section 506C of the Federal 
        Food, Drug, and Cosmetic Act (21 U.S.C. 356c) (relating to 
        notification of any discontinuance or interruption in the 
        production of life-saving drugs).
            (2) The term ``drug'' has the meaning given to such term in 
        section 201 of the Federal Food, Drug, and Cosmetic Act (21 
        U.S.C. 321).
                                 <all>